LENZ Therapeutics (LENZ) Competitors $31.62 -1.78 (-5.33%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$31.86 +0.23 (+0.74%) As of 07/25/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LENZ vs. ACAD, PTCT, ZLAB, ACLX, VKTX, SWTX, AAPG, PTGX, MLTX, and HCMShould you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include ACADIA Pharmaceuticals (ACAD), PTC Therapeutics (PTCT), Zai Lab (ZLAB), Arcellx (ACLX), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), Ascentage Pharma Group International (AAPG), Protagonist Therapeutics (PTGX), MoonLake Immunotherapeutics (MLTX), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. LENZ Therapeutics vs. Its Competitors ACADIA Pharmaceuticals PTC Therapeutics Zai Lab Arcellx Viking Therapeutics SpringWorks Therapeutics Ascentage Pharma Group International Protagonist Therapeutics MoonLake Immunotherapeutics HUTCHMED ACADIA Pharmaceuticals (NASDAQ:ACAD) and LENZ Therapeutics (NASDAQ:LENZ) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk. Do insiders & institutionals believe in ACAD or LENZ? 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 26.5% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better valuation and earnings, ACAD or LENZ? ACADIA Pharmaceuticals has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioACADIA Pharmaceuticals$957.80M4.06$226.45M$1.3716.97LENZ TherapeuticsN/AN/A-$49.77M-$1.77-17.86 Do analysts prefer ACAD or LENZ? ACADIA Pharmaceuticals presently has a consensus price target of $28.13, indicating a potential upside of 20.97%. LENZ Therapeutics has a consensus price target of $46.60, indicating a potential upside of 47.38%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ACADIA Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.71LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Is ACAD or LENZ more profitable? ACADIA Pharmaceuticals has a net margin of 22.97% compared to LENZ Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 17.46% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ACADIA Pharmaceuticals22.97% 17.46% 10.75% LENZ Therapeutics N/A -23.74%-22.65% Does the media refer more to ACAD or LENZ? In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than LENZ Therapeutics. MarketBeat recorded 12 mentions for ACADIA Pharmaceuticals and 4 mentions for LENZ Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 1.20 beat LENZ Therapeutics' score of 1.13 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ACAD or LENZ? ACADIA Pharmaceuticals has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. SummaryACADIA Pharmaceuticals beats LENZ Therapeutics on 13 of the 15 factors compared between the two stocks. Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENZ vs. The Competition Export to ExcelMetricLENZ TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$940.08M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.69%4.01%P/E Ratio-17.8621.1828.1020.06Price / SalesN/A283.55428.7189.11Price / CashN/A42.7636.2258.56Price / Book4.268.378.665.87Net Income-$49.77M-$55.19M$3.25B$258.55M7 Day Performance-6.26%5.88%4.22%3.73%1 Month Performance5.01%17.33%10.51%11.75%1 Year Performance31.91%4.42%34.40%18.02% LENZ Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENZLENZ Therapeutics1.5609 of 5 stars$31.62-5.3%$46.60+47.4%+31.4%$940.08MN/A-17.86110News CoverageGap UpACADACADIA Pharmaceuticals4.2562 of 5 stars$22.28-1.2%$27.88+25.1%+25.3%$3.78B$996.28M16.26510Positive NewsAnalyst ForecastPTCTPTC Therapeutics4.4327 of 5 stars$47.86+0.5%$65.00+35.8%+33.3%$3.78B$1.77B7.351,410News CoveragePositive NewsZLABZai Lab3.1865 of 5 stars$34.66+3.2%$54.28+56.6%+97.0%$3.73B$398.99M-13.921,869Positive NewsGap UpACLXArcellx2.3525 of 5 stars$69.39+2.7%$111.23+60.3%+13.8%$3.72B$107.94M-23.2180News CoveragePositive NewsVKTXViking Therapeutics4.8503 of 5 stars$31.94-0.2%$87.15+172.9%-46.8%$3.60BN/A-27.7720Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionSWTXSpringWorks Therapeutics1.349 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230AAPGAscentage Pharma Group InternationalN/A$39.71-1.7%N/AN/A$3.52B$134.35M0.00600Lockup ExpirationGap DownPTGXProtagonist Therapeutics1.381 of 5 stars$55.22-0.5%$66.10+19.7%+32.7%$3.44B$434.43M73.63120News CoverageInsider TradeMLTXMoonLake Immunotherapeutics2.1665 of 5 stars$53.57+0.9%$74.50+39.1%+22.6%$3.40BN/A-23.292News CoverageOptions VolumeHCMHUTCHMED2.7604 of 5 stars$17.74+0.9%$19.00+7.1%-2.2%$3.07B$630.20M0.001,811Analyst Forecast Related Companies and Tools Related Companies ACAD Competitors PTCT Competitors ZLAB Competitors ACLX Competitors VKTX Competitors SWTX Competitors AAPG Competitors PTGX Competitors MLTX Competitors HCM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LENZ) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredThe AI Chip Trade is OUT. This is in…Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LENZ Stock Alerts